CN103788196B - Polypeptide, the detection means comprising this polypeptide and detection kit - Google Patents

Polypeptide, the detection means comprising this polypeptide and detection kit Download PDF

Info

Publication number
CN103788196B
CN103788196B CN201210422933.0A CN201210422933A CN103788196B CN 103788196 B CN103788196 B CN 103788196B CN 201210422933 A CN201210422933 A CN 201210422933A CN 103788196 B CN103788196 B CN 103788196B
Authority
CN
China
Prior art keywords
polypeptide
diabetes
present
detection means
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210422933.0A
Other languages
Chinese (zh)
Other versions
CN103788196A (en
Inventor
马宏伟
刘星
黄沫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Institute of Nano Tech and Nano Bionics of CAS
Original Assignee
Suzhou Institute of Nano Tech and Nano Bionics of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Institute of Nano Tech and Nano Bionics of CAS filed Critical Suzhou Institute of Nano Tech and Nano Bionics of CAS
Priority to CN201210422933.0A priority Critical patent/CN103788196B/en
Publication of CN103788196A publication Critical patent/CN103788196A/en
Application granted granted Critical
Publication of CN103788196B publication Critical patent/CN103788196B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to polypeptide, comprise the detection means of this polypeptide and detection kit.Is polypeptide of the present invention by SEQ? ID? aminoacid sequence shown in NO:1 is formed.Polypeptide of the present invention, the detection means comprising this polypeptide and detection kit are useful in the diagnosis of diabetes.

Description

Polypeptide, the detection means comprising this polypeptide and detection kit
Technical field
The present invention relates generally to polypeptide, comprises the detection means of this polypeptide and detection kit, belongs to biological technical field.
Background technology
Diabetes ( diabetesMellitus, DM) clinical syndrome of to be jointly caused by h and E factor one group with carbohydrate metabolism disturbance be main manifestations.Insulin deficit and insulin action obstacle cause the metabolism disorder of carbohydrate, fat, protein, power and water medium etc. individually or simultaneously, and clinical take chronic hyperglycemia as principal character.Can be there is diuresis in model case, drink, eat more more, the performance such as to become thin, i.e. " three-many-one-little " symptom.
At European diabetes association (EuropeanAssociationfortheStudyofDiabetes, EASD) in meeting in 2011, IDF (InternationalDiabetesFederation, IDF) issue latest data display: within 2011, whole world diabetes number of patients has reached 3.66 hundred million, compared with 2010 2.85 hundred million increase nearly 30%.4,600,000 people are had to die from diabetes every year, for the medical expense of diabetes up to 4,650 hundred million dollars.Chairman IDF professor JeanClaudeManbaya says: " in 2011, just there were 1 people in every 7 seconds because of Diabetes Death, and alarm bell is beaten ".According to sound in the November, 2011 of China, diabetic subject's number that China has made a definite diagnosis, up to 9,240 ten thousand people, is the first in the world.In the adult in more than 20 years old, the whole nation, onset diabetes rate is up to 9.7%.
Diabetes can be divided into type 1 diabetes, diabetes B, gestational diabetes and specific type diabetes by the classification of its nosetiology.
The clinical manifestation of Hospitals at Present Main Basis is (as type 1 diabetes is mainly in adolescence, and have typical " three-many-one-little " symptom, depend on Regular Insulin etc.) distinguish 1 type and diabetes B, to the indefinite diabetic subject of somatotype as adult's delayed autoimmune diabetes (latentautoimmunediabetesinadults, LADA) and make a definite diagnosis type 1 diabetes and then need to detect type 1 diabetes autoantibody and carry out auxiliary diagnosis.
Summary of the invention
The object of the present invention is to provide a kind of to diabetes, the polypeptide that particularly diagnosis of type 1 diabetes is useful, to encode the nucleic acid of this polypeptide, comprise the expression vector of this nucleic acid, import the host cell of this expression vector, the antibody of this polypeptide anti-, comprise the detection means of this polypeptide, comprise the detection kit of this polypeptide or this detection means, and this polypeptide is detecting the purposes in type 1 diabetes, this polypeptide is for the preparation of the purposes detected in the test kit of type 1 diabetes or detection means.
That is, the present invention comprises following technical proposals:
1. the polypeptide be made up of the aminoacid sequence shown in SEQIDNO:1.
2. the nucleic acid of coding polypeptide according to claim 1.
3. comprise the expression vector of nucleic acid according to claim 2.
4. imported the host cell of expression vector according to claim 3.
5. a detection means, it comprises:
Solid carrier, and
Be connected to the polypeptide according to claim 1 on this solid carrier.
6. detection means according to claim 5, wherein, described solid carrier is SJ modified silica-gel.
7. a detection kit, it comprises the detection means described in polypeptide according to claim 1 or claim 5 or 6.
8. the antibody of anti-polypeptide according to claim 1.
9. polypeptide according to claim 1 is for the preparation of the purposes detected in the test kit of type 1 diabetes or detection means.
Polypeptide of the present invention is applied to the diagnosis of diabetes (particularly type 1 diabetes), gratifying effect can be obtained.
Accompanying drawing explanation
Polypeptide is fixed on the schematic diagram on SJ modified silica-gel surface by Fig. 1 by chemical covalent.
The HPLC that the of the present invention polypeptide of Fig. 2 to chemosynthesis confirms characterizes collection of illustrative plates.
The MS that the of the present invention polypeptide of Fig. 3 to chemosynthesis confirms characterizes collection of illustrative plates.
The schematic diagram that the making processes of Fig. 4 to SJ modified silica-gel (iPDMS film) is described.
The figure that Fig. 5 is described polypeptide microarrays chemistry fixation procedure.
Fig. 6 illustrates the schematic diagram of polypeptide microarrays spot sample mode.
Fig. 7 ~ 8 show the photo to the result that different serum detects.
Embodiment
polypeptide of the present invention
Polypeptide of the present invention is 30 peptides.30 peptides of the present invention are made up of the aminoacid sequence shown in SEQIDNO:1, that is: EEAVPEEEGPTVVLNPHPSLGYKEIRKGES.As shown in the Examples, it is positive to the serum of type 1 diabetes patient, and to be negative reaction to healthy normal people or non-type 1 diabetes patients serum.Therefore, this 30 peptide is useful as the diagnostic tool of type 1 diabetes.
Polypeptide of the present invention, when having commercially available, can use commercially available product, and in addition, can also be suitable for adopting the known method such as (1) chemical synthesis process or (2) enzyme reaction synthetic method to obtain, wherein chemosynthesis is more easy.In chemosynthesis polypeptide situation of the present invention, undertaken by using peptide synthesizer synthesis or this polypeptide semi-synthetic.As chemical synthesis process, such as peptide solid-phase synthesis etc. can be listed.The peptide of such synthesis can adopt conventional means such as ion-exchange chromatography, reverse phase high performance liquid chromatogram, affinity chromatography etc. to carry out purifying.Such peptide solid phase synthesis process with and subsequent peptide purification be all well-known in the art.
In addition, when producing polypeptide of the present invention by enzyme reaction, the method such as described in No. WO2004/011653, International Publication brochure can be adopted.Namely; can produce like this: by the amino acid of a side or the C-terminal of dipeptides is esterified or amidation and the amino acid that obtains or dipeptides, the amino acid (amino acid of such as carboxy protective) that is in unbound state with amino acid react under the existence of peptide synthetase, the dipeptides of generation or tripeptides.As peptide synthetase, can list: there is the culture of microorganism of the ability generating peptide, the bacterial disposing thing of the microbial cells be separated by this culture or this microorganism or this microbe-derived peptide synthetase.
And except above-mentioned enzyme method, chemical synthesis process, in some cases, polypeptide of the present invention may be also natural existence (but not being separated).In naturally occurring situation, can also be separated.
nucleic acid of the present invention, expression vector host cell, and the antibody of anti-polypeptide of the present invention
The invention still further relates to the nucleic acid (nucleic acid of the present invention) of this polypeptide of coding, comprise the expression vector (expression vector of the present invention) of this nucleic acid, imported the host cell (host cell of the present invention) of this expression vector, they preferably can be used for producing polypeptide of the present invention.Nucleic acid of the present invention, expression vector, host cell can adopt the method for well known to a person skilled in the art to prepare.The invention still further relates to the antibody of anti-polypeptide of the present invention, it can be used for detecting antibody of the present invention.Antibody of the present invention can adopt the method for well known to a person skilled in the art to prepare.
detection means of the present invention
The invention still further relates to a kind of detection means (detection means of the present invention), it comprises solid carrier and is connected to the polypeptide of the present invention on this solid carrier.
In the present invention, solid carrier is not particularly limited, as long as the carrier of solid or insoluble material (be such as can pass through filtration, material that precipitation, magnetic resolution etc. are separated from reaction mixture).
The material forming solid carrier includes but not limited to: silica gel (polydimethylsiloxane, PDMS), Mierocrystalline cellulose, teflon tM, Nitrocellulose, agarose, dextran, chitosan, polystyrene, polyacrylamide, polyester, polycarbonate, polymeric amide, polypropylene, nylon, poly(vinylidene fluoride), latex, silicon-dioxide, glass, glass fibre, gold, platinum, silver, copper, iron, stainless steel, ferrite, silicon wafer, polyethylene, polymine, poly(lactic acid), resin, polyose, albumen (albumin etc.), carbon or their combination etc.
The shape of solid carrier comprises but is not limited to: pearl, magnetic bead, film, microcapillary, filter membrane, plate, micro plate, carbon nanotube, sensor chip etc.Just as known in the art, the solid carrier that film or plate etc. are smooth can be arranged bottom pit, groove, filter membrane etc.
In the present invention, magnetic bead can have the sphere diameter of about 25nm ~ about 1mm scope.In a preferred embodiment, magnetic bead has the diameter of about 50nm ~ about 10 μm scope.The size of magnetic bead can be selected according to specific purposes.
In the present invention, the pearl be made up of the contour crosslinked spherical agarose of Sepharose has the diameter of about 24 μm ~ about 165 μm of scopes.Preferably, high crosslinked spherical sepharose 4B has the diameter of about 24 μm ~ about 44 μm of scopes.The size of high crosslinked spherical sepharose 4B can be selected according to specific purposes.
The example with the solid carrier of water repellent surface comprises can from Polysciences, Warrington, PA or Spherotech, the polystyrene latex beads such as the goods that Liberville, IL buy.
Silicon-dioxide (SiO 2)-process or silicon-dioxide (SiO 2) example of solid carrier of base comprises the extraordinary magnetic silica pearl etc. can bought from Polysciences, Warrington, PA, it may be used for catching nucleic acid (such as DNA).Or, the M-280 etc. that can buy from DynalBiotech can also be used.
The magnetic bead with hydrophilic surface can be used for the bacterial cell of seizure proliferation period, nucleic acid and other composition.As the example of this magnetic bead, Polysciences can be listed, Warrington, the pearl (title: Biomag (registered trademark) carboxyl) that PA sells or BangsLaboratory, Inc., the name of Fishers, IN is called the pearl of MC02N/2928.Or, the M-270 etc. that DynalBiotech sells can be used.
In a preferred embodiment of the present invention, described solid carrier is SJ modified silica-gel.The microarray solid support material (iPDMS film, see Chinese patent CN101265329A) of a kind of silicon rubber material of Suzhou Siju Biomaterials Co., Ltd.'s exploitation.This material is based on the conventional PDMS of biological study, add specific initiator composition (making this material realize surface-functionalized modification by surface initiated polymerization (SIP)) wherein, obtain through polyethylene glycol methacrylate-styrene polymer (poly (oligo (ethyleneglycol) methacrylate), pOEGMA) finishing again.SJ modified silica-gel has outstanding anti-protein non-specific adsorption (Nonspecificproteinadsorption, NPA) ability, non-specific protein absorption in complicated protein immunization can being detected controls to close to " absolute 0 " level (being near or below the limit of detection of instrument), not only can exempt the trouble closed and repeatedly clean, can also by the susceptibility using stronger amplification of signal means to improve protein microarray.And the essence of its silicon rubber imparts the stronger mechanical property of this material and good operability.Suzhou Yvonne gathers the combination assay microarray ELISA kit that SJ modified silica-gel has successfully been applied to 11 tumor markers compositions by company, achieve high-throughput and high-sensitive detection, demonstrating this material is a kind of outstanding protein microarray solid support material.Meanwhile, this material also has the adjustable characteristic of surface properties, can adjust its surface topography within the specific limits by the controlled modification reaction times.
The connection of polypeptide of the present invention and solid carrier can adopt the method for attachment that well known to a person skilled in the art polypeptide and solid carrier to carry out.Such as, for the connection on protein/polypeptide and modified silica-gel surface, 1-ethyl-3-(3-dimethyl aminopropyl)-carbodiimide [1-ethyl-3-(3-dimethylami-nopropyl) carbodiimide can be passed through, EDC] and N-hydroxy-succinamide (N-hydroxysuccinimide, NHS) reaction changes the carboxyl (-COOH) group on the macromolecular chain of modified silica-gel surface into activating group, this activating group can with protein/polypeptide on amino (-NH2) react thus realize protein/polypeptide being fixed on solid carrier surface (see Fig. 1).
Concentration for polypeptide of the present invention in the sampling liquid used during point sample is not particularly limited, and those skilled in the art can conventionally select, and is preferably 1 μ g ~ 1000 μ g/mL, more preferably 10 μ g ~ 500 μ g/mL.In addition, the density distributed on a solid support for polypeptide of the present invention is not particularly limited, and those skilled in the art can conventionally select, and is preferably 1 ~ 100 points/10mm 2, more preferably 5 ~ 50 points/10mm 2.
Detection means of the present invention may be used for detecting diabetes (particularly type 1 diabetes) or the test kit for the preparation of detection diabetes (particularly type 1 diabetes).
detection kit of the present invention
The invention still further relates to a kind of detection kit (detection kit of the present invention), it comprises polypeptide of the present invention or detection means.This detection kit is preferred for detecting diabetes (particularly type 1 diabetes).
Detection means of the present invention or polypeptide of the present invention are the important documents of detection kit of the present invention.Detection kit of the present invention can also comprise:
1. the serum dilution prepared or serum dilution component solution: serum dilution, such as, have the Sample dilution (production code member 070021-S2) of Sai Chi bio tech ltd, Beijing, the application of sample variable color Sample dilution (production code member bwj010103) etc. of Bo Weijia bio tech ltd, Zhengzhou.This serum dilution is used for dilute serum, and the serum that test kit detects will dilute suitable multiple, such as 2 ~ 200 times, preferably 10 ~ 100 times.
Detection kit of the present invention can also comprise:
2. concentrated washing lotion: after solid carrier surface hatches serum and ELIAS secondary antibody, the unconjugated antibody of solid carrier surface and ELIAS secondary antibody need be washed by washing lotion.Concentrated washing lotion is such as the polysorbas20 aqueous solution of 1%, need dilute 2 ~ 40 times, preferably 5 ~ 20 times during use.
Detection kit of the present invention can also comprise:
3. ELIAS secondary antibody solution: the type 1 diabetes autoantibody in type 1 diabetes patients serum can be combined by the polypeptide of the present invention on solid carrier (such as SJ modified silica-gel), two anti-can with antibodies, and two markers resisted can react with luminous substrate, thus send detectable light.ELIAS secondary antibody can be the goat anti-human igg of such as horseradish peroxidase-labeled.As ELIAS secondary antibody solution, the Goat anti human IgG (H+L) of the horseradish peroxidase-labeled that Beijing Bioisystech Co., Ltd of Zhong Shan Golden Bridge produces can be listed, production code member ZB-2304.Being not particularly limited the concentration of ELIAS secondary antibody in ELIAS secondary antibody solution, can be such as 1ng ~ 1000ng/mL.
Detection kit of the present invention can also comprise:
4. luminescent solution component solution: luminescent solution can react with the two anti-upper horseradish peroxidases marked, and makes to react the chemical light sending instrument and can detect.Luminescent solution is mixed by two kinds of solution, is A liquid-superoxol respectively, and B liquid-luminol solution.Luminol (luminol,3-aminophthalic acid cyclic hydrazide) only has crosses just meeting luminescence by oxidizer treatment.The mixed aqueous solution of usual use hydrogen peroxide and a kind of hydroxide bases is as exciting agent.Under horseradish peroxidase enzyme catalytic, decomposing hydrogen dioxide solution is oxygen G&W:
2H 2O 2→O 2+2H 2O
Luminol,3-aminophthalic acid cyclic hydrazide and oxyhydroxide generate a pairs of anion when reacting, the dioxygen oxidation that it can be gone out by peroxide decomposition, and product is an organo-peroxide.This superoxide is very unstable, decomposites nitrogen immediately, generates the 3-aminophthalic acid of excited state.During excited state to ground state transforms, the energy of release exists with the form of photon, and wavelength is positioned at the blue light components of visible ray.The SuperSignal ELISAFemtoMaximumSensitivitySubstrate of the example such as ThermoSeientific company of luminescent solution component solution, article No. 37074.
Detection kit of the present invention can also comprise:
5. one or more reaction cavity (such as Chinese patent Granted publication CN202054829U).
Detection kit of the present invention can also comprise:
6. other are for detecting the detection molecules (such as polypeptide, protein, nucleic acid etc.) of diabetes (particularly type 1 diabetes).
Detection kit of the present invention can also comprise:
7. working instructions.
Embodiment
Below, by embodiment, more specific description is carried out to the present invention, but be not the restriction to the technology of the present invention scope.By the record of this specification sheets, those skilled in the art can be easy to modify the present invention/change, and these are included in technical scope of the present invention.
the preparation of 1.30 peptides and confirmation
30 peptides used in embodiment have the aminoacid sequence shown in SEQIDNO:1, and synthesized by Chu Tai bio tech ltd, Shanghai, Fig. 2 and Fig. 3 be shown in by the sign collection of illustrative plates of this polypeptide, can confirm to have synthesized described polypeptide.
2. the preparation of detection means
Detection chip be with SJ modified silica-gel (iPDMS film) for solid support material, be prepared from by point sample immobilized polypeptide solution thereon.Modified silica-gel be add in traditional polydimethyl siloxane material band olefin-terminal, the initiator of surface initiated polymerization, and be fixed in the three-dimensional structure of polydimethylsiloxane by heat cross-linking (si-h bond bonding), obtain a kind of new material and SJ modified silica-gel.Its making processes as shown in Figure 4.
A and B is wherein two components of polydimethylsiloxane, polydimethylsiloxane (Poly (dimethylsiloxane), Sylgard184) buy from Dow corning (DowCorning) company, comprising liquid composition A(composition is metallic platinum catalyst and the diformazan siloxanes polymer precursor mixture being with vinyl) and crosslinking agent B (composition is the dimethyl siloxane precursor with vinyl and Si-H group) two kinds of compositions.C is the initiator of end strips vinyl, is purchased from Hangzhou Dong Wei company.Polymer on finally modifying is that oligomeric ethylene glycol methacrylate monomer (Oligo (ethyleneglycol) methacrylate, hereinafter referred to as OEGMA, molecular weight Mw=526) is bought in Aldrich.Polydimethylsiloxane precursor A and crosslinking agent B are fully mixed with A:B:C=10:1:0.5 ratio with the initiator C of band vinyl end.Make transparent elastic silicone rubber by curing reaction, then carry out finishing by sip technique and can obtain SJ modified silica-gel.Experiment shows, the surface of SJ modified silica-gel have enough highdensity, by the initiator of covalently immobolization, it can pass through surface initiated polymerization (SIP), and to realize surface macromolecule modified.The surface that reaction acquisition polyoxyethylene glycol (PolyethyleneGlycol, PEG) is modified is carried out in use poly (OEGMA) (polyethylene glycol methacrylate-styrene polymer), realizes the ability of stronger anti-albumen non-specific adsorption.
The SJ modified silica-gel film made need be kept in 4 DEG C of refrigerators.
Adopt brilliant core ?personalArrayerTM16 people's point sample instrument prepares polypeptide microarrays on modified silica-gel, and process is:
1) pre-treatment
By SJ modified silica-gel thin slice (15 × 15mm 2) be immersed in activation solution, take out with deionized water drip washing 3 times after 30min, dry up with nitrogen, be used for point sample at once.
2) point sample
Sampling liquid is diluted and gets well and transfer in the corresponding micropore of 384 orifice plate, 384 orifice plates of band sample are placed on point sample instrument base station, pretreated modified silica-gel thin slice are placed on the base station of point sample instrument simultaneously, carry out point sample at once.Point sample envrionment conditions is room temperature (25 DEG C), and humidity set is 50%.On the polypeptide microarrays made, the point sample amount of each point is about 0.6nL, and sampling point radius is 200 μm.
3) chemistry is fixing
The polypeptide microarrays just made will be placed on fixing at least 6h in climatic chamber (26 DEG C, 60% humidity).Chemistry fixation procedure as shown in Figure 5.
First by point sample instrument by include catch peptide molecule damping fluid point on modified silica-gel film, then damping fluid starts evaporation, catch peptide molecule and the surface intimate contact interacting of SJ modified silica-gel, by Chemical bond, the high molecular end-COOH of ploy (OEGMA) on modified silica-gel surface and peptide molecule-NH 2formed and stablize covalent linkage, and then chemically active peptide molecule will be had to be fixed on SJ modified silica-gel surface.
5) assemble
The polypeptide microarrays of fixing 6h must assemble in two days.First by gum, SJ modified silica-gel thin slice is attached on special reaction column, covers reaction cavity.A reactor is made up of two reaction columns and a reaction cavity.
6) preserve
The polypeptide microarrays assembled, needs to vacuumize sealing, is kept in the refrigerator of 4 DEG C, for subsequent use.
3. detect by detection means
Checking procedure
1, before starting to detect, concentrated cleaning solutions is added purified water in the ratio of 1:10 or distilled water dilutes, diluted rear direct use.Use liquid-transfering gun that 2mL scavenging solution is added to chip surface, soak chip 3 minutes, ensure that chip surface is fully wet out.
2, test serum sample Sample dilution is mixed according to 1:40 dilution.
3, discard the scavenging solution soaking chip, under the state that chip surface is completely moistening, the serum after each serum sample draws 200 μ L dilutions joins in chip reactor.
4, chip reactor is put into chip permanent seat, be put on shaking table, open shaking table, frequency 150 revs/min, incubated at room 30 minutes.
5, the serum sample in chip reactor is discarded, with 15mL washing lotion cleaning reaction cavity and chip surface 3 times.
6, after having cleaned, each chip reactor adds 200 μ L enzyme labelled antibody solution respectively, chip reactor is put into chip permanent seat, is put on shaking table, opens shaking table, frequency 150 revs/min, incubated at room 30 minutes.
7, the enzyme labelled antibody solution in chip reactor is discarded, with 15mL washing lotion cleaning reaction cavity and chip surface 3 times.
8, after having cleaned, take off reaction cavity, each chip surface adds 15 μ L luminous substrate liquid respectively, makes luminescent solution can be laid on chip surface uniformly.
9, the chip adding luminescent solution is placed in gel imaging instrument chemiluminescence imaging, and sentence read result.
Type 1 diabetes patients serum and other disease patient's serum samples are provided by chain hospital.Serum is transported by related personnel with parcels such as ice cube/dry ice or is handed to laboratory soon.
Negative control has the contrast of PBS damping fluid (namely hatch without test serum in the 3rd step, and hatch by PBS solution, all the other steps are identical), the contrast of serum dilution, and the contrast of patients with negative (referring to Healthy People and non-type 1 diabetes patient) serum.
The spot sample mode of polypeptide microarrays as shown in Figure 6.Wherein, the sample of leg-of-mutton 20 points is human IgG, as the locating point of experiment; The sample of foursquare 12 points is PB sampling liquid, as the blank of experiment; The sample polypeptides of star point is polypeptide SEQIDNO:1 of the present invention, has three to repeat a little, and it is type 1 diabetes autoantigen protein polypeptide, can produce response to type 1 diabetes patients serum; Circular point sample be other type 1 diabetes autoantigen protein polypeptide, as the Testing index (these polypeptide have response to illustrate detect in serum have type 1 diabetes autoantibody) of experiment.
Experimental result is as shown in Fig. 7 ~ 8.Wherein, Fig. 7 shows the detected result of negative control, only has the sample of the point shown in trilateral to have response.Fig. 8 shows the detected result of type 1 diabetes patients serum, and the sample of trilateral, star point and/or circle has response.It should be noted that, instrument records signal value from low to high, and corresponding signaling point color is by black-white gradual change.

Claims (8)

1. the polypeptide be made up of the aminoacid sequence shown in SEQIDNO:1.
2. the nucleic acid of coding polypeptide according to claim 1.
3. comprise the expression vector of nucleic acid according to claim 2.
4. imported the host cell of expression vector according to claim 3.
5. a detection means, it comprises:
Solid carrier, and
Be connected to the polypeptide according to claim 1 on this solid carrier.
6. detection means according to claim 5, wherein, described solid carrier is iPDMS film.
7. a detection kit, it comprises the detection means described in polypeptide according to claim 1 or claim 5 or 6.
8. polypeptide according to claim 1 is for the preparation of the purposes detected in the test kit of type 1 diabetes or detection means.
CN201210422933.0A 2012-10-30 2012-10-30 Polypeptide, the detection means comprising this polypeptide and detection kit Active CN103788196B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210422933.0A CN103788196B (en) 2012-10-30 2012-10-30 Polypeptide, the detection means comprising this polypeptide and detection kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210422933.0A CN103788196B (en) 2012-10-30 2012-10-30 Polypeptide, the detection means comprising this polypeptide and detection kit

Publications (2)

Publication Number Publication Date
CN103788196A CN103788196A (en) 2014-05-14
CN103788196B true CN103788196B (en) 2016-01-27

Family

ID=50664289

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210422933.0A Active CN103788196B (en) 2012-10-30 2012-10-30 Polypeptide, the detection means comprising this polypeptide and detection kit

Country Status (1)

Country Link
CN (1) CN103788196B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101265329A (en) * 2007-03-16 2008-09-17 马雄明 Polydimethylsiloxane with initiator on surface and its preparation method and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101265329A (en) * 2007-03-16 2008-09-17 马雄明 Polydimethylsiloxane with initiator on surface and its preparation method and use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
chromogranin A [Homo sapiens],GI:180529;Helman,L.J et al;《GenBank》;19941231;氨基酸序列 *
Chromogranin A is an autoantigen in type 1 diabetes;Stadinski BD et al;《Nat Immunol》;20100331;第11卷(第3期);摘要 *

Also Published As

Publication number Publication date
CN103788196A (en) 2014-05-14

Similar Documents

Publication Publication Date Title
CN103665138B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN103788195B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN104098685B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN104098674B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN103788199B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN104098677A (en) Polypeptide, and detection member and detection kit both containing same
CN103788196B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN103788198B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN103788194B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN103788202B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN103788203B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN103788201B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN103788200B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN104098680B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN104098684B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN103788183B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN104098686B (en) Polypeptide, the detection means comprising this polypeptide and detection kit
CN104098667A (en) Polypeptide, and detection member and detection kit both containing same
CN103788197A (en) Polypeptide, detector comprising polypeptide and detection kit
CN103788205A (en) Polypeptide, detection device containing polypeptide and detection kit
CN103788204A (en) Polypeptide, detection device containing polypeptide and detection kit
CN104098654A (en) Polypeptide, and detection member and detection kit both containing same
CN104098672A (en) Polypeptide, and detection member and detection kit both containing same
CN104098679A (en) Polypeptide, and detection member and detection kit both containing same
CN104098682A (en) Polypeptide, and detection member and detection kit both containing same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant